22 Recruiting Studies Using Belzutifan
Active clinical trials that use this intervention, sourced directly from the NIH registry.
Browse by conditionTrials Using Belzutifan
Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A)
π University of California at San Francisco ( Site 1008) β San Francisco, California
Carcinoma, Renal Cell
View Study & Checklist βA Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011)
π Ironwood Cancer & Research Centers ( Site 0077) β Chandler, Arizona
Carcinoma, Renal Cell
View Study & Checklist βSubstudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus (2L+) Renal Cell Carcinoma (MK-3475-03B/KEYMAKER-U03)
π University of California at San Francisco ( Site 3008) β San Francisco, California
Carcinoma, Renal Cell
View Study & Checklist βA Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)
π The University of Alabama at Birmingham ( Site 0010) β Birmingham, Alabama
Carcinoma, Renal Cell
View Study & Checklist βA Study of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Clear Cell Renal Cell Carcinoma Post Nephrectomy (MK-6482-022)
π Mayo Clinic in Arizona - Phoenix ( Site 3554) β Phoenix, Arizona
Carcinoma, Renal Cell
View Study & Checklist βA Study of Belzutifan (MK-6482) in Participants With Advanced Renal Cell Carcinoma (MK-6482-013)
π Georgetown University Medical Center ( Site 0002) β Washington D.C., District of Columbia
Carcinoma, Renal Cell
View Study & Checklist βPembrolizumab Plus Lenvatinib in Combination With Belzutifan in Solid Tumors (MK-6482-016)
π University of Arizona Cancer Center-University of Arizona Cancer Center - North Campus ( Site 5047) β Tucson, Arizona
Neoplasm Malignant
View Study & Checklist βStudy of Belzutifan (MK-6482) Plus Fulvestrant for ER+/HER2- Metastatic Breast Cancer (MK-6482-029/LITESPARK-029)
π City of Hope - Phoenix ( Site 0006) β Goodyear, Arizona
Metastatic Breast Cancer
View Study & Checklist βA Phase 2 Study of Belzutifan (PT2977, MK-6482) for the Treatment of Von Hippel Lindau (VHL) Disease-Associated Renal Cell Carcinoma (RCC) (MK-6482-004)
π National Institutes of Health Clinical Center β Bethesda, Maryland
VHL - Von Hippel-Lindau Syndrome
View Study & Checklist βA Study of Belzutifan (MK-6482) Versus Everolimus in Participants With Advanced Renal Cell Carcinoma (MK-6482-005)
π Faculty Office Towers 1132 ( Site 1538) β Birmingham, Alabama
Carcinoma, Renal Cell
View Study & Checklist βA Study of Belzutifan (MK-6482) in Combination With Palbociclib Versus Belzutifan Monotherapy in Participants With Advanced Renal Cell Carcinoma (MK-6482-024/LITESPARK-024)
π Georgetown University Medical Center ( Site 1002) β Washington D.C., District of Columbia
Renal Cell Carcinoma
View Study & Checklist βA Trial of Belzutifan (PT2977, MK-6482) in Combination With Cabozantinib in Patients With Clear Cell Renal Cell Carcinoma (ccRCC) (MK-6482-003)
π USC Norris Comprehensive Cancer Center ( Site 0060) β Los Angeles, California
Renal Cell Carcinoma (RCC)
View Study & Checklist βA Clinical Study of Belzutifan (MK-6482) and Zanzalintinib in People With Renal Cell Carcinoma (RCC) (LITESPARK-034/LS-034/MK-6482-034)
π Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital ( Site 0102) β Marietta, Georgia
Carcinoma, Renal Cell
View Study & Checklist βBelzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2Ξ± Related Genetic Alterations (MK-6482-015)
π Cedars-Sinai Medical Center ( Site 0110) β Los Angeles, California
Pheochromocytoma/Paraganglioma
View Study & Checklist βBelzutifan's Role in Active Surveillance Versus Treatment for Indolentmetastatic Clear Cell Renal Ccell Carcinoma (BRAVE-RCC)
π MD Anderson Cancer Center β Houston, Texas
Active Surveillance
View Study & Checklist βEffects of Belzutifan on 89Zr-DFO-girentuximab PET Uptake in Patients With Renal Cell Carcinoma (RCC)
π NYU Langone Health β New York, New York
Metastatic Clear Cell Renal Cell Carcinoma
View Study & Checklist βExtension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043)
π Beth Israel Deaconess Medical Center ( Site 0107) β Boston, Massachusetts
Von Hippel-Lindau Disease
View Study & Checklist βSubstudy 03C: A Study of Combination Therapies in Participants With Renal Cell Carcinoma With Recurrent Disease During or After Anti-PD-(L)1 Therapy (MK-3475-03C/KEYMAKER-U03)
π UCSF Medical Center at Mission Bay ( Site 5008) β San Francisco, California
Renal Cell Carcinoma
View Study & Checklist βBelzutifan in Recurrent Clear Cell Carcinoma of Gynecologic Origin
π Brigham and Women's Hospital β Boston, Massachusetts
Ovarian Cancer
View Study & Checklist βPhase II Trial of Single Agent Belzutifan or Pembrolizumab Versus Combination as Neoadjuvant Therapy in Clear Cell Renal Cell Carcinoma (BLAZE)
π The University of Texas M. D. Anderson Cancer Center β Houston, Texas
Clear Cell Renal Cell Carcinoma
View Study & Checklist βA Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033)
π Alaska Oncology and Hematology ( Site 0133) β Anchorage, Alaska
Renal Cell Carcinoma
View Study & Checklist βA Study of HC-7366 in Combination With Belzutifan (WELIREGβ’) in Patients With Renal Cell Carcinoma
π University of Arizona Cancer Center β Tucson, Arizona
Renal Cell Carcinoma
View Study & Checklist β